… investors gear up for an earnings-heavy week (Tesla, Microsoft, … of an expected deep freeze.  Eisai (ESALY) and Biogen (BIIB): … The FDA accepted for review Eisai’s supplemental application for a … Treasury Auction And on the earnings radar, investors will be …

… movements. Overview of Past Earnings Last quarter the company … likely bearish going into this earnings release. Analysts' … ), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's … increase in top-line earnings. When compared to others …

… operational efficiencies, are expanding Eisai's eligible patient … diversification, and long-term earnings stability as the aging … their price target: an earnings surge and margin boost … suggests Eisai is undervalued, its price-to-earnings ratio …

… of the biopharma house, Q2 earnings are in full swing, with … week ahead of its own earnings report, Novo Nordisk named a … -month timeframe for Biogen and Eisai’s Leqembi and Eli Lilly …

… treatment with Biogen and Eisai’s anti-amyloid antibody … ’ press announcement. Biogen and Eisai’s readout on Wednesday additionally … upward track, Biogen and Eisai are now shifting their promotion … the company’s fourth-quarter earnings call in February. “I …

… amp; Co., Inc. beats earnings expectations. Reported EPS is $ … J., USA Q2 Sales and Earnings Conference Call. [Operator Instructions … slides, along with the earnings release, today’s prepared … collaboration with our collaborator, Eisai. In relationship to the …

… this optimistic start to Q2 earnings season a good sign … heading into the second-quarter earnings season, Jefferies’ Michael Yee … the third quarter, which Eisai in February suggested could be … submissions next year. Biogen and Eisai do “not expect sales …

… earnings call last week. CEO Haruo Naito described on the call Eisai … recently diagnosed patients, Eisai wants to boost understanding … begins treatment. Overall, Eisai is aiming to increase … awareness-raising efforts.  Eisai’s earnings presentation included a …

… first quarter of 2025 adjusted earnings per share was $3.02 … April, the European Commission approved Eisai Co., Ltd. ESALY and Biogen …

… use of the drug, prompting Eisai to express at the time … in the third quarter of Eisai’s 2024 fiscal year, which … of a “growth expansion phase,” Eisai’s chief operating and growth … Naito said during a February earnings call. Improvements in awareness, …